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Neuroinflammation is one of the most striking hall-
marks of amyotrophic lateral sclerosis (ALS). Nuclear
factor-kappa B (NF-kB), a master regulator of inflam-
mation, is upregulated in spinal cords of ALS patients
and SOD1-G93Amice. In this study, we show that se-
lective NF-kB inhibition in ALS astrocytes is not suf-
ficient to rescue motor neuron (MN) death. However,
the localization of NF-kB activity and subsequent
deletion of NF-kB signaling in microglia rescued
MNs from microglial-mediated death in vitro and
extended survival in ALS mice by impairing proin-
flammatory microglial activation. Conversely, consti-
tutive activation of NF-kB selectively in wild-type
microglia induced gliosis and MN death in vitro and
in vivo. Taken together, these data provide a mecha-
nism by which microglia induce MN death in ALS and
suggest a novel therapeutic target that can bemodu-
lated to slow the progression of ALS and possibly
other neurodegenerative diseases by which micro-
glial activation plays a role.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating, fast-
progressing neurodegenerative disease characterized by motor
neuron (MN) death in the brainstem, spinal cord, and motor cor-
tex. Typically within 2–5 years of clinical onset, patients succumb
to the disease due to severe muscle atrophy, paralysis, and ulti-
mately denervation of respiratory muscles. Most ALS cases are
classified as sporadic, defined as having no family history of the
disease. The remaining 5%–10% of cases are classified as
familial and are typically inherited in an autosomal dominant
fashion. Despite genetic differences, these two forms of ALS
are clinically indistinguishable. Approximately 20% of familialcases are associated with mutations in the gene superoxide dis-
mutase 1 (SOD1) (Rosen et al., 1993). Transgenic rodents car-
rying mutant forms of SOD1 develop a similar, progressive MN
disease akin to patients and are used as the gold standard in
ALS research. Elegant studies using these animals have shown
that nonneuronal cells play a crucial role in ALS, contributing to
MN death via non-cell-autonomous mechanisms (Clement
et al., 2003). Similarly, in vitro studies have shown that murine
astrocytes and microglia expressing mutant SOD1 and human
astrocytes from sporadic and familial ALS patients can induce
MN death (Di Giorgio et al., 2007, 2008; Haidet-Phillips et al.,
2011; Marchetto et al., 2008; Nagai et al., 2007; Xiao et al.,
2007). Evidence that individual cell types mediate different
aspects of disease emerged from the generation of mice
expressing a conditional deletion of the mutant SOD1 gene.
Removal of mutant SOD1 specifically in MNs extended survival
by delaying disease onset and early disease progression, while
excising floxed mutant SOD1 in either microglia/macrophages
or astrocytes extended survival by slowing disease progression,
but not onset (Boille´e et al., 2006; Yamanaka et al., 2008). Simi-
larly, replacing the myeloid lineage of mutant SOD1 mice with
wild-type (WT) microglia/macrophages slowed disease pro-
gression (Beers et al., 2006). This suggests ALS is a deadly
convergence of damage developed in multiple cellular compart-
ments that ultimately leads to neuromuscular failure. However,
the precise mechanisms by which individual cell types such
as astrocytes and microglia contribute to the disease remain
unknown.
One of the most striking hallmarks of ALS shared by familial
and sporadic patients, as well as by rodent models, is neuroin-
flammation, characterized by extensive astrogliosis, microglial
activation, and infiltration of peripheral immune cells at sites of
neurodegeneration (Alexianu et al., 2001; Hall et al., 1998; Kawa-
mata et al., 1992; Mantovani et al., 2009; Turner et al., 2004).
Mutant SOD1 astrocytes andmicroglia exhibit increased expres-
sion of many proinflammatory genes (Philips and Robberecht,
2011). However, genetic approaches to globally eliminate single
inflammatory genes in ALS mouse models have largely failed to
extend survival (Almer et al., 2006; Gowing et al., 2006; NguyenNeuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc. 1009
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tened disease progression (Lerman et al., 2012), highlighting the
complexity of neuroinflammation in ALS. For these reasons, a
successful therapeutic approach is likely to derive from a better
understanding of the intricate molecular mechanisms driving the
inflammatory response and the identification of upstream tran-
scription factors that are dysregulated in each cellular compart-
ment throughout the course of disease.
Classical NF-kB signaling involving the p65/p50 heterodimer
is a major regulator of inflammation, driving gene expression of
proinflammatory cytokines, chemokines, enzymes, and adhe-
sion molecules, many of which are upregulated in ALS. When
inflammatory mediators bind their respective receptors, a
signaling cascade is initiated that leads to phosphorylation and
activation of IKKb (a subunit of the inhibitor of IkB kinase [IKK]
complex). Activated IKKb phosphorylates the IkB inhibitory
protein IkBa, targeting it for ubiquitination and proteasomal
degradation and subsequent release of NF-kB (p65/p50) to the
nucleus where it binds to its cognate DNA sequences to induce
gene expression (Ghosh and Karin, 2002). Additionally, phos-
phorylation by IKKb at specific serine residues is required for
transactivation function of the p65 subunit of NF-kB (Hayden
and Ghosh, 2008). We previously reported NF-kB as the high-
est-ranked regulator of inflammation by Ingenuity Pathway Anal-
ysis of inflammatory gene array data from astrocytes derived
from human postmortem ALS patients (Haidet-Phillips et al.,
2011). Other laboratories have confirmed by immunohistochem-
istry that NF-kB is activated in glia in familial and sporadic ALS
patients (Swarup et al., 2011). Interestingly, loss-of-function mu-
tations in the gene optineurin, which is known to negatively regu-
late TNF-a-induced NF-kB activation, have been found in ALS
patients (Maruyama et al., 2010). However, it remains unknown
whether NF-kB activation in ALS glia is involved in MN death.
Since the role of glial-derived inflammation in ALS remains
ambiguous, we sought to determine whether inflammatory
signaling regulated by NF-kB in astrocytes and microglia medi-
ates MN death in ALS. In the current study, we demonstrate
that NF-kB is activated with disease progression in the SOD1-
G93Amousemodel, specifically in glia. In agreement with recent
publications, inhibition of NF-kB in astrocytes, using both trans-
genic and viral-mediated gene delivery approaches, did not
increasemotor function or survival in our SOD1-G93Amice (Cro-
sio et al., 2011). However, inhibition of NF-kB selectively in
microglia rescues MN survival in vitro, and, in vivo, extends sur-
vival in the ALS mice by delaying disease progression by 47%,
one of the longest extensions reported in this severe model.
NF-kB inhibition in microglia leads to marked reduction in proto-
typic inflammatory markers, suggesting that NF-kB regulates
microglial conversion to a proinflammatory, neurotoxic state in
ALS. Conversely, we show that constitutive activation of
NF-kB selectively in myeloid cells in WT mice creates the patho-
logical features of ALS in the spinal cord (i.e., gliosis and MN
death). Together, these data indicate that NF-kB activation in
microglia is a novel molecular mechanism underlying MN death
in ALS. Moreover, the data identify a new therapeutic target to
modulate microglial activation and slow the progression of ALS
and possibly other neurodegenerative diseases in which micro-
glial activation plays a role.1010 Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc.RESULTS
NF-kB Is Activated with Disease Progression in the
SOD1-G93A Mouse Model of ALS
In order to gain insight into NF-kB regulation in ALS, we per-
formed electrophoretic mobility shift assay (EMSA) analysis on
whole-spinal-cord nuclear lysates from the SOD1-G93A mouse
model. NF-kB DNA binding activity was increased in end-stage
ALS mice compared to WT littermates (Figure S1A available
online). Supershift EMSA analysis revealed the binding contribu-
tion of p65 (Figure S1B). Interestingly, we were unable to show a
supershift using antisera against p50, c-Rel, and RelB subunits,
whichmay bemore of a limitation of the antibody than the lack of
presence of these NF-kB subunits in spinal cords of SOD1-G93A
mice. To investigate the extent of p65-mediated classical NF-kB
activation in the SOD1-G93A mouse model at different stages of
disease, whole-lumbar spinal cord protein was analyzed for
the transcriptionally active, phosphorylated form of p65 from
three SOD1-G93A female mice at the presymptomatic stage
(pre-sym), disease onset, symptomatic (sym), late-symptomatic
(late-sym), and end-stage (ES). We found that as diseased pro-
gressed in ALS animals, phospho-p65 levels increasedmodestly
from pre-sym to sym, although fold changes were not statis-
tically significant. However, at late-sym, phospho-p65 levels
were 13.7-fold greater in SOD1-G93A mice compared to WT
and 8.7-fold greater than WT at ES (Figures 1A and 1B). In order
to determine whether the increase in phospho-p65 levels
observed at late-sym stages is statistically different compared
to the levels at ES, we analyzed lumbar spinal cord lysates
from additional late-sym (n=6) and ES SOD1-G93A mice (n=6),
revealing no statistical difference in NF-kB activation between
late-sym and ES (Figures S1C and S1D). To determine the contri-
bution of astrocytes to this increase, we isolated primary astro-
cytes from the spinal cords of WT and SOD1-G93A mice at the
late-sym stage. Western blot analysis showed a 4.4-fold in-
crease in phospho-p65 in ALS astrocytes compared to WT
(Figure 1C).
NF-kB Inhibition in Astrocytes Does Not Confer
Neuroprotection In Vitro or In Vivo in the SOD1-G93A
Mice
To determine the relevance of NF-kB activation to astrocyte-
mediated MN death in ALS, we tested NF-kB inhibition in an
in vitro coculture model of familial ALS. We utilized an embryonic
stem cell line containing an Hb9-GFP reporter, which we and
others have shown recapitulate aspects of MN pathology and
cell death when cocultured with ALS glia (Di Giorgio et al.,
2007; Haidet-Phillips et al., 2011; Nagai et al., 2007; Wichterle
et al., 2002). After 5 days in coculture, the number of MNs pre-
sent on SOD1-G93A astrocytes was statistically reduced by
49% compared to the MNs surviving on WT astrocytes (Fig-
ure S2A). To test the role of NF-kB in SOD1-G93A astrocytes,
we utilized an adenovirus expressing the transdominant super
repressor inhibitor of NF-kB (IkBa-SR). IkBa-SR is an IkBa
mutant that is resistant to phosphorylation-induced degradation,
thus blocking phosphorylation sites of p65 and inhibiting tran-
scriptional function of the NF-kB complex (Wang et al., 1999).
We confirmed that adenoviral vectors were capable of targeting
Figure 1. The Classical NF-kB Pathway Is
Activated with Disease Progression in the
SOD1-G93A Mouse Model and Astroglial
NF-kB Inhibition Does Not Confer Neuropro-
tection
(A and B) Immunoblot (A) and fold changes (B) of
lumbar spinal cord protein isolated fromWTmice at
120 days and from SOD1-G93A female mice at
presymptomatic (Pre-sym), onset (Onset), symp-
tomatic (Sym), late-symptomatic (Late-sym), and
end-stage (ES). Phospho-p65 (top) total p65 (mid-
dle) and Actin (bottom). n=3. Additional data shown
in Figure S1.
(C) Immunoblot of protein isolated from astrocytes
obtained from late-sym SOD1-G93A and WT
littermates.
(D and E) Kaplan-Meier survival curve (D) of SOD1-
G93A mice injected with AAV9-IkBa-SR (median
survival=128; n=16) and noninjected controls
(median survival=136.5; n=14) and motor perfor-
mance on accelerating rotarod test (E).
(F and G) Kaplan-Meier survival curve (F) of SOD1-
G93A; IKKbf/f; GFAP-cre (median survival=154;
n=10) and SOD1-G93A; IKKbf/f; GFAP-cre+ mice
(median survival=149; n=14) and motor perfor-
mance on accelerating rotarod test (G). All band
intensities were normalized to p65/Actin. Error bars
represent SEM. *p<0.05; **p<0.01. See also Fig-
ures S1 and S2.
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et al., 2012). However, overexpression of IkBa-SR in SOD1-
G93A astrocytes did not rescue MN death in vitro, despite being
functional and decreasing phospho-p65 levels (Figures S2A and
S2B). In fact, there were fewer MNs surviving after 4 days in
coculture with SOD1-G93A astrocytes overexpressing IkBa-SR
compared to SOD1-G93A astrocytes; however, significance
was lost on subsequent days (Figure S2A).
Since our in vitromodel may not fully recapitulate all aspects of
astrocyte-induced pathology in ALS, we simultaneously tested
NF-kB inhibition in vivo using two independent, cell-type-spe-
cific approaches: viral-mediated gene delivery and transgenic
cre-lox recombination. As a therapeutically relevant study, we in-
jected SOD1-G93A mice with adeno-associated viral vector
serotype 9 (AAV9) to deliver IkBa-SR.Micewere injected at post-Neuron 81, 1009–102natal day 60 to preferentially target >50%
astrocytes in the CNS (Foust et al., 2009,
2013). Consistent with the in vitro data
above, overexpression of IkBa-SR in
astrocytes utilizing AAV9 neither altered
survival nor improved motor performance
in the SOD1-G93A mice compared to
noninjected controls (Figures 1D and 1E)
or SOD1-G93A mice injected with AAV9-
GFP (Foust et al., 2013).
To transgenically inhibit NF-kB in astro-
cytes in SOD1-G93A mice, we mated
SOD1-G93Amice tomice with conditional
mutants of IKKb (IKKbf/f), which have exon
3 of the ikbkb (IKKb) gene flanked by loxPsites (Li et al., 2003; Park et al., 2002). We crossed these mice to
a strain expressing cre recombinase under the regulation of the
glial fibrillary acidic protein (GFAP) promoter, thus ablating IKKb
and downstream NF-kB activity specifically in astrocytes. We
confirmed cre expression was restricted to GFAP-expressing
astrocytes in the spinal cord by crossing GFAP-cre mice to a
Rosa26 line that expresses tdTomato (RFP) in all cre-expressing
cells (Figure S2C). We observed robust RFP expression in
GFAP+ and EAAT2+ cells (Figure S2D); RFP expression was
absent in Iba-1+microglia aswell as in ChAT+ neurons in the spi-
nal cord as previously reported (Figure S2C) (Yamanaka et al.,
2008; Zhuo et al., 2001). Immunoblot of lumbar spinal cord pro-
tein demonstrated a 58% reduction in phospho-p65 levels in
SOD1; IKKbf/f; GFAP-cre+ mice compared to SOD1 cre mice
at the symptomatic stage of disease (Figure S2E). Despite the3, March 5, 2014 ª2014 Elsevier Inc. 1011
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GFAP-cre+ mice were not improved compared to GFAP-cre-
negative controls (Figures 1F and 1G). Indeed, our findings are
consistent with a recent study crossing ALS mice to a strain
overexpressing IkBa-SR under the GFAP promoter (Crosio
et al., 2011).
NF-kB Activation Occurs Predominately in Microglia in
the SOD1-G93A Mouse Model
To evaluate whether astrocytes are the main cells contributing to
the increase in lumbar NF-kB activation, we crossed the SOD1-
G93A mice to a NF-kB-GFP reporter mouse strain that ex-
presses GFP under the control of NF-kB cis elements (Magness
et al., 2004). Since robust NF-kB activation in SOD1-G93A was
evident at late stages of disease in lumbar spinal cord protein,
we analyzed lumbar spinal cord sections from late-sym SOD1;
NF-kB-GFPmice for GFP expression.We observed a population
of bright GFP+ cells identified as microglia by overlapping
confocal Iba-1 staining (Figure 2A). We also observed a dim
GFP+ population of GFAP+ astrocytes (Figure 2B). We con-
firmed these findings by analyzing phospho-p65 levels in protein
from microglia isolated from late-sym SOD1-G93A mice.
Impressively, phospho-p65 was 12.4-fold greater in SOD1-
G93A microglia than WT microglia (Figure 2C). To determine
the time course of NF-kB activation in microglia as disease
progressed, we performed immunohistochemistry of SOD1;
NF-kB-GFP lumbar spinal cord sections at pre-sym, onset,
sym, late-sym, and ES. We observed that majority of bright
and dim GFP+ cells colocalized with the microglial marker
tomato lectin at disease onset with an increase in the number
and GFP intensity as disease progressed, coinciding with micro-
glial activation and gliosis (Figures 2D and 2E). These data reveal
that microglia contribute to the robust NF-kB activation that
occurs during ALS disease progression.
Adult SOD1-G93A Microglia Are Toxic to MNs In Vitro
To study the mechanisms by which microglia mediate MN death
in ALS and the contribution of NF-kB activation to this process,
we sought to establish an in vitro coculture model of ALS. We
found no difference in MN survival when MNs were cocultured
with SOD1-G93A primary neonatal microglia compared to WT
(Figure S3), suggesting these young cells were not recapitulating
important aspects of the adult-onset neurodegenerative dis-
ease. Therefore, we established a coculture utilizing primary
adult microglia isolated from symptomatic ALSmice. We utilized
a previously described method that combines density separa-
tion and culture selection (Moussaud andDraheim, 2010). Immu-
nocytochemical characterization of adult microglia obtained by
this method showed that microglia were positive for prototypic
microglial markers including Iba-1, CD11b, and F4/80 and
negative for GFAP, ChAT, and NG2 (Figures 3A and 3B). Flow
cytometry confirmed that this technique yields a homogenous
population of microglia (Figure 3C). We observed no difference
in our assays when we used spinal-cord- or brain-derived micro-
glia; therefore, to decrease the number of animals used, we per-
formed experiments using brain microglia.
To determine the capacity for SOD1-G93A adult microglia to
induce MN death, we cocultured WT Hb9:GFP+ MNs with WT1012 Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc.or SOD1-G93A microglia. After 72 hr, MN numbers decreased
50% when cocultured with SOD1-G93A microglia compared to
WT microglia (Figures 3D and 3E). To confirm that MN death is
specific to the causative SOD1 mutation, we overexpressed a
shRNA targeting the human SOD1 transgene in the SOD1-
G93A microglia by lentivirus, shown to reduce mutant protein
by 75% (Figure 3F). When mutant SOD1 protein was reduced
in SOD1-G93A microglia, MNs survival was rescued (Figures
3D and 3E).
Adult SOD1-G93A Microglia Induce MN Death in an
NF-kB-Dependent Mechanism In Vitro
To examine whether NF-kB activation in microglia is involved
in MN death in vitro, we employed two independent approaches
to abolish NF-kB activation in microglia. First, we overexpressed
IkBa-SR via adenovirus (Ad-IkBa-SR) in SOD1-G93A and WT
microglia. We also used a genetic approach by isolating
microglia fromSOD1-G93A; IKKbf/f mice and infecting themicro-
glia in vitro with an adenovirus expressing cre recombinase
(Ad-cre) to remove IKKbf/f in microglia postisolation. After
12 hr, we observed no difference in survival or axon length of
the MNs cocultured with SOD1-G93A or WT microglia (Fig-
ure 4A). However, after 72 hr of coculture there was a 61%
reduction in MN survival and marked reduction in axon length
when MNs were cocultured with SOD1-G93A microglia
compared to WT (Figure 4B). Live imaging of these cocultures
captures the dynamic nature of microglia and rapid MN death
induced by SOD1-G93A microglia (Movies S1 and S2). Initially,
WT microglia phagocytosed MN debris generated from the
FACS sorting and plating. WT microglia then proceeded to
actively survey synapses of MNs, not disrupting intact synapses.
On the contrary, SOD1-G93A microglia assaulted intact synap-
ses, thus causing axonal damage and MN death, finishing with
phagocytosis of the neuronal debris. Remarkably, NF-kB inhibi-
tion, either transgenically or by overexpression of IkBa-SR, fully
rescued MN axon length and survival in vitro to WT levels (Fig-
ures 4A and 4B). Live imaging shows SOD1-G93A microglia
with NF-kB inhibition preserved intact MNs similar to WT micro-
glia (Movies S3 and S4). We evaluated the efficiency of NF-kB
induction by measuring nitric oxide (NO) and TNF-a levels in
the coculture medium, both of which are products of classical
NF-kB activation and inflammatory microglia (Ghosh and Karin,
2002). TNF-a levels decreased by 45% and by 64% when
NF-kBwas inhibited in SOD1-G93Amicroglia using Ad-IkBa-SR
and Ad-cre, respectively (Figure 4C). NO levels were reduced by
71% and by 56% in SOD1-G93A microglia using Ad-IkBa-SR
and Ad-cre, respectively (Figure 4D). Corresponding with
TNF-a and NO levels, phospho-p65 was reduced by 79% and
81% using Ad-IkBa-SR and Ad-cre, respectively, compared to
SOD1-G93A microglia (Figure 4E). To confirm NF-kB transcrip-
tional activity was reducedwith Ad-IkBa-SR and Ad-cre, we per-
formed an NF-kB luciferase assay. Firefly luciferase activity
normalized to renilla luciferase was 6.2-fold greater in SOD1-
G93A microglia compared to WT, and Ad-IkBa-SR and Ad-cre
both reduced NF-kB-dependent luciferase activity in SOD1-
G93Amicroglia to nearWT levels (Figure 4F). These data suggest
that SOD1-G93A microglia induce MN death in an NF-kB-
dependent mechanism.
Figure 2. NF-kB Activation Occurs Predominately in Microglia in the SOD1-G93A Mouse Model
(A and B) Representative high-magnification images of NF-kB-GFP-positive cells (green) in the lumbar ventral horn of late-symptomatic NF-kB EGFP;SOD1-G93A
mice. Most predominant GFP+ cells (A) also positive for microglial marker Iba1 (red). Other GFP+ cells positive for astrocyte maker GFAP (blue). Scale bar in-
dicates 5 mm in (A) and 20 mm in (B).
(C) Immunoblot of protein isolated from primary microglia obtained from late-sym SOD1-G93A mice and WT littermates. Fold change determined by phospho-
p65 band intensity normalized to p65/Actin.
(D) Immunohistochemistry of lumbar ventral horn of WT; NF-kB -GFP at 120 days and SOD1-G93A; NF-kB -GFP mice pre-sym, onset, sym, late-sym, and ES.
NF-kB activation shown by NF-kB EGFP (green), and microglia and vasculature shown by tomato lectin (red). Scale bar indicates 50 mm.
(E) Quantification of GFP+ cells colocalizing with tomato lectin in lumbar spinal cord sections of SOD1-G93A; NF-kB -GFP mice. Error bars represent SEM.
**p<0.01; ****p< 0.0001.
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Figure 3. Adult SOD1-G93A Microglia Are Toxic to MNs In Vitro
(A and B) Immunocytochemistry of WT and SOD1-G93A microglia for prototypic microglial markers Iba-1, CD11b, and F4/80 and astrocytes (GFAP),
oligodendrocyte precursors (NG2), and MNs (ChAT). Quantification per well (B). DAPI (blue) Scale bar indicates 20 mm.
(C) Flow cytometry of adult microglia for CD45 and CD11b.
(D and E) Representative microscopic field (D) and quantification of well (E) of surviving Hb9-GFP+MNs after 3 days (72 hr) of coculture with either WT or SOD1-
G93A microglia that were not infected (black bars) or infected with Lv-RFP (dashed bars) or Lv-shRNA-SOD1 (white bars). Scale bar indicates 200 mm.
(F) Quantification of human SOD1 protein in SOD1-G93A microglia infected with Lv-RFP and Lv-shRNA-SOD1 determined by ELISA. Error bars represent SEM.
***p< 0.001; ****p<0.0001. See also Figure S3.
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Since we have established that (1) NF-kB activation during the
disease course in SOD1-G93Amice occurs inmicroglia (Figure 2)
and (2) SOD1-G93A microglia kill MNs in vitro via an NF-kB-
dependent mechanism (Figure 4), we tested the hypothesis
that NF-kB inhibition in microglia would attenuate disease in
SOD1-G93A mice. To do so, we crossed SOD1-G93A; IKKbf/f
mice to mice expressing cre recombinase driven by the pro-
moter for the gene c-fms, which encodes Colony stimulating
factor receptor 1 (CSF-1R). As shown by MacGreen reporter
mice that express GFP under the regulation of the c-fms pro-
moter, CSF-1R is expressed throughout the mononuclear
phagocyte system of the mouse, but only microglia express
CSF-1R in the postnatal mouse brain (Erblich et al., 2011; Sas-
mono and Williams, 2012; Sasmono et al., 2003). To confirm
cell-type specificity of cre expression driven by the c-fms
(CSF-1R) promoter, we crossed CSF-1R-cre mice to the
Rosa26-Td-Tomato mouse strain. We observed RFP expression
only in Iba-1-positive microglia in the adult mouse spinal cord,1014 Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc.and RFP expression was absent in MNs and astrocytes (Figures
S4A and S4B).
Mice homozygous for IKKb (IKKbf/f), both SOD1 and WT, dis-
played serious immune dysfunction, such as enlarged spleens,
eye infections, and missing or very brittle teeth, which have
been previously reported in mice with myeloid cells devoid of
NF-kB (Ruocco et al., 2005; Vallabhapurapu and Karin, 2009).
These mice could not be maintained in the colony long enough
to evaluate survival; thus, we analyzed IKKbf/wt heterozygous
mice. To determine the efficiency of IKKb knockdown in these
heterozygotes, immunohistochemistry was performed probing
for IKKb in lumbar spinal cord sections from SOD1-G93A;
IKKbf/wt; CSF-1R-cre+ and cre mice. SOD1-G93A; IKKbf/wt;
CSF-1R-cre+ showed a decrease in IKKb staining compared
to cre negative controls (Figure S4C). To ensure knock down
was specific for IKKb, we evaluated IKKg, the regulatory subunit
of the IKK signaling complex, and observed no difference be-
tween CSF-1R-cre+ and cre mice (Figure S4C). Remarkably,
reducing IKKb, and thus NF-kB activation, resulted in a pro-
nounced 20 day extension in median survival in SOD1-G93A;
Neuron
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(133 days in cre and 153 days in cre+) (Figure 5A). While dis-
ease onset was not altered (102.8 ± 1.1 days in cre and
101.1 ± 1.3 days in cre+), disease progression was significantly
extended by 47% in cre+ mice compared to cre mice (34.8 ±
1.4 days in cre and 51.1.1 ± 1.7 days in cre+) (Figures 5B
and 5C). Video of age-matched littermates show SOD1-G93A;
IKKbf/wt; CSF-1R-cre+ mouse able to ambulate around cage
while the SOD1-G93A; IKKbf/wt; CSF-1R-cre littermate is at
ES (Movie S5). To confirm the level of NF-kB inhibition that
was achieved to slow disease progression by 47%, we analyzed
lumbar spinal cord protein for phospho-p65 from SOD1-G93A;
IKKbf/wt; CSF-1R-cre+ or cre mice at ES. Remarkably,
phospho-p65 was reduced by 44% in SOD1-G93A; IKKbf/wt;
CSF-1R-cre+ mice compared to cre SOD1 controls, which ex-
pressed 7.5-fold more phospho-p65 than WT controls. This is
consistent with the 40% decrease in IKKb we observed in
SOD1-G93A; IKKbf/wt; CSF-1R-cre+ mice compared to cre
controls (Figure 5D). Notably, NF-kB inhibition did not reduce
the levels of mutant SOD1 in CSF-1R-cre+ mice compared to
cre SOD1 control mice (Figure 5D).
To determine the impact of NF-kB inhibition on astrogliosis
and microgliosis, we analyzed lumbar spinal cord sections by
immunohistochemistry for intensity of GFAP and Iba-1, respec-
tively. No difference in gliosis could be detected between ES
SOD1-G93A; IKKbf/wt; CSF-1R-cre+ and cre mice (data not
shown). However, considering that SOD1-G93A; IKKbf/wt;
CSF-1R-cre+ mice endured disease for an additional 3 weeks
compared to controls, it is possible that differences in gliosis
achieved earlier in disease are lost at ES. Indeed, when we
sacrificed the SOD1-G93A; IKKbf/wt; CSF-1R-cre+ mice at the
same age as the cre littermate controls reached endpoint, we
observed a significant decrease in signal intensity of GFAP
by 31% and of Iba-1 by 25%, indicating astrogliosis and micro-
gliosis are decreased in CSF-1R-cre+ mice compared to age-
matched controls (Figures 5E–5G).
NF-kB Regulates SOD1-G93A Microglial Conversion to
an Inflammatory, Neurotoxic Phenotype
We hypothesized that the increased survival observed in SOD1-
G93A; IKKbf/wt; CSF-1R-cre+ mice was due to a dampened
inflammatory microglial response. To characterize microglial
phenotype, antibodies specific for CD68, iNOS, and CD86
were used to label microglia exhibiting an M1 inflammatory
phenotype (Kigerl et al., 2009). As disease progresses, we and
others have observed SOD1-G93A mice exhibit a robust induc-
tion in CD68-positive microglia that is greatest at ES (data not
shown) (Beers et al., 2011b; Chiu et al., 2013). We found a
marked reduction in the number of CD68 positive microglia
in SOD1-G93A; IKKbf/wt; CSF-1R-cre+ mice (112.4 ± 4.7 cells/
section) compared to cre-negative controls (438.3 ± 13.4 cells/
section) (Figures 6A and 6B). The number of iNOS+/Iba1+
cells/section was also significantly reduced from 251.1 ± 15.0
in controls to 47.8 ± 3.1 in mice with microglial NF-kB inhibition
(Figures 6C and 6D). Following the same trend, mice with micro-
glial NF-kB inhibition showed substantial reduction of CD86+/
Iba1+ cells (97.8 ± 7.4 per section) compared to SOD1 controls
(320.3 ± 15.6 cells per section) (Figures 6E and 6F). We did notobserve any alterations in the M2 markers CD206, arginase, or
CD204 by immunohistochemistry, suggesting that while we in-
hibited M1 microglia, NF-kB inhibition did not promote an M2
phenotype (data not shown).
NF-kB Activation Selectively in WT Microglia Is
Sufficient to Induce MN Death In Vitro
We hypothesized that if NF-kB activation is the mechanism by
which SOD1-G93A microglia induce MN death, constitutively
activating NF-kB in WT microglia should be sufficient to induce
MN death. To test this hypothesis, we isolated microglia from
Rosa26-StopFloxIKKbCA mice containing inducible constitu-
tively active IKKb (IKKb CA). Postisolation, we infected microglia
from these mice with an adenovirus expressing cre recombinase
(Ad-cre) to induce transcription of constitutively active IKKb
(microglia termed IKKbCA) or Ad-RFP as control (microglia
termed WT). After 12 hr in coculture with WT or IKKbCA micro-
glia, we observed no difference in MN axon length or survival
(Figure 7A). Interestingly, after 72 hr in coculture, IKKbCAmicro-
glia induced a 50% statistical decrease inMN survival compared
to controls (Figures 7A and 7B). Live-imaging shows IKKbCA
microglia rapidly inducing MN death (Movie S6). We confirmed
NF-kB activation by ELISA, showing 1.7-fold greater phospho-
p65/total p65 in IKKbCA microglia compared to WT (Figure 7C).
Similarly, NF-kB-dependent luciferase activity normalized to re-
nilla was 1.5-fold greater in IKKbCA microglia compared to WT
(Figure S5A). Additionally, TNF-a levels increased 2.3-fold in
cocultures with IKKbCA microglia compared to WT, which is
comparable to TNF-a induction by SOD1-G93A microglia and
characteristic of activated microglia (Figure S5B). Similarly, NO
levels in IKKbCA microglia/MN coculture were 1.5-fold greater
than WT (Figure S5C). These data suggest that constitutive
NF-kB activation in microglia is sufficient to induce MN death in-
dependent of SOD1 mutations.
NF-kB Regulates Microglial Activation to an
Inflammatory, Neurotoxic Phenotype
Since we observed a reduction in inflammatory microglial
markers CD68, iNOS, and CD86 with NF-kB inhibition, we hy-
pothesized that NF-kB is required for microglial activation.
Thus, we reasoned that selectively expressing constitutively
active IKKb (IKKbCA) in myeloid cells in vivo should induce an in-
flammatory state in WT microglia similar to that observed in ALS
mice. To test this notion, we crossed mice expressing CSF-1R-
cre to Rosa26-StopFloxIKKbCA mice (termed IKKbCA). IKKbCA
mice exhibited an 8.2-fold increase in phospho-p65 in lumbar
spinal cord protein compared to cre-negative littermates, similar
to levels in SOD1-G93A mice (Figure 7D). Enhanced microglial
activation at 4 and 8 months in these mice also was associated
with pronounced astrocytosis (Figure 7E). By 8 months, we
observed a striking 40% decrease in ChAT+ MNs in the lumbar
spinal cord (Figure 7F), which coincided with decreased mass
and hind-limb grip strength in IKKbCA mice compared to WT lit-
termates (Figures 7G and 7H). Thus, chronic activation of NF-kB
signaling in myeloid cells creates the pathological features of
ALS in the spinal cord (i.e., gliosis and MN death). While we
focused on lumbar spinal MNs, it is likely other neurons and brain
regions are affected by microglial activation in IKKbCA mice.Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc. 1015
(legend on next page)
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Figure 5. SOD1-G93A Microglia Induce MN Death in an NF-kB-Dependent Mechanism In Vivo
(A) Kaplan-Meier survival curve of SOD1-G93A; IKKbF/wt; CSF1R-cre (n=22) and SOD1-G93A; IKKbF/wt; CSF-1R-cre+ mice (n=25). Median survival of SOD1-
G93A; IKKbF/wt; CSF1R-cre is 133 days and of SOD1-G93A; IKKbF/wt; CSF-1R-cre+ is 153 days. Mean survival for SOD1-G93A; IKKbF/wt; CSF1R-cre is
134.9 ± 1.4 days and for SOD1-G93A; IKKbF/wt; CSF-1R-cre+ is 153.7 ± 0.9 days, with p<.0001.
(B) Disease onset determined by age at which peak weight was reached. SOD1-G93A; IKKbF/wt; CSF1R-cre-reached onset at 102.8 ± 1.1 days, and SOD1-G93A;
IKKbF/wt; CSF1R-cre+ mice reached onset at 101.1 ± 1.3 days.
(C) Disease progression defined as time from disease onset to ES. SOD1-G93A; IKKbF/wt; CSF1R-cremean disease progression is 34.8 ± 1.4 days, and SOD1-
G93A; IKKbF/wt; CSF1R-cre+ mean disease progression is 51.1 ± 1.7 days.
(D) Immunoblot of lumbar spinal cord protein isolated from WT; IKKbF/wt; CSF1R-cre+, WT; IKKbF/wt; CSF1R-cre-, and ES SOD1-G93A; IKKbF/wt; CSF1R-cre-,
SOD1-G93A; IKKbF/wt CSF1R-cre+ mice probed for phospho-p65 (top), total p65, IKKb, human SOD1, and Actin (bottom). Fold change represents band
intensities of phospho-p65 normalized to p65/Actin and IKKb normalized to actin.
(E) Immunohistochemistry of Iba1-positive microglia (red) and GFAP-positive astrocytes (green) in the lumbar spinal cords of ES SOD1-G93A; IKKbF/wt CSF1R-
cre, age-matched SOD1-G93A; IKKbf/wt CSF1R-cre+, and WT IKKbf/wt CSF1R-cre+ littermates. Scale bar indicate 200 mm.
(F and G) Quantification of GFAP and Iba-1 signal intensity in SOD1-G93A; IKKbF/wt CSF1R-cre and age-matched SOD1-G93A; IKKbf/wt CSF1R-cre+
immunohistochemistry in represented in (E). Error bars represent SEM. ***p< 0.001. See also Figure S4 and Movie S5.
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Microglia Induce Motor Neuron Death by NFkB in ALSTo determine whether microglia in IKKbCA mice express acti-
vation markers, similar to those described above for activated
(M1) microglia from SOD1-G93A mice, we analyzed microglia
from the IKKbCA and cre-negative littermates for expression of
CD68, iNOS, and CD86. A striking upregulation of CD68 andFigure 4. Adult SOD1-G93A Microglia Induce MN Death in an NF-kB-D
(A and B) Representative microscopic fields (A) and well counts (B) of Hb9-GFP+
microglia not infected (black bars), infectedwith Ad-RFP (dashed bars), or infected
G93A; IKKbf/f microglia infected with Ad-cre shown with dashed bars. Scale bar
(C and D) Quantification of TNF-a (C) and nitric oxide (D) in the coculture medium
(E) Quantification of phospho-p65 by ELISA from microglial-MN cocultures. Pho
(F) Luciferase assay of NF-kB activity in microglia. Firefly luciferase normalized to r
Movies S1, S2, S3, and S4.CD86 was observed in microglia from 4-month- and 8-month-
old IKKbCAmice (Figures S6A and S6B). Microglia from IKKbCA
mice also differed drastically from those found inWT controls ex-
hibiting a deramified morphology with shorter, thickened pro-
cesses shown by Iba-1 staining. We detected an increase inependent Mechanism In Vitro
MNs after 1 day (24 hr) and 3 days (72 hr) in coculture with WT or SOD1-G93A
with Ad-IkBa-SR (white bars). MNs coculturedwith eitherWT; IKKbf/f or SOD1-
indicate 200 mm.
by ELISA.
spho-p65 normalized to total p65 determined by ELISA.
enilla luciferase. Error bars represent SEM. ****p< 0.0001; ***p< 0.001. See also
Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc. 1017
Figure 6. NF-kB Inhibition in SOD1-G93A Microglia Impairs Microglial Activation to a Proinflammatory, Neurotoxic Phenotype
(A and B) Immunohistochemistry (A) and quantification (B) of CD68 (red) and Iba1 (green) cells in lumbar spinal cord of disease-matched ES SOD1-G93A; IKKbF/wt
CSF1R-cre and SOD1-G93A; IKKbF/wt CSF1R-cre+ littermates. Scale bar indicates 200 mm.
(C andD) Immunohistochemistry (C) and quantification (D) of iNOS (red) and Iba1 (green) cells in lumbar spinal cord of disease-matched ES SOD1-G93A; IKKbF/wt
CSF1R-cre and SOD1-G93A; IKKbF/wt CSF1R-cre+ littermates. Scale bar indicates 20 mm.
(E and F) Immunohistochemistry (E) and quantification (F) of CD86 (red) and Iba1 (green) cells in lumbar spinal cord of disease-matched ES SOD1-G93A; IKKbF/wt
CSF1R-cre and SOD1-G93A; IKKbF/wt CSF1R-cre+ littermates. Scale bar indicates 20 mm. Error bars represent SEM. ****p< 0.0001.
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at 4 months in IKKbCA mice (Figure S6C). Interestingly, we
observed an increase in CD68 and CD86-positive microglia in
8 month WT controls compared to 4 month-old controls, which
supports previous reports that microglial activation increases
with aging (Norden and Godbout, 2013). These data suggest
that chronic NF-kB activation induces an inflammatory (M1)
microglia phenotype that causes MN death (Figures 8A and 8B).
DISCUSSION
Landmark studies have shown selective removal of the causal
mutant SOD1 gene from myeloid cells in the slow-progressing
SOD1-G37R mice (Boille´e et al., 2006) or repopulating the fast-
progressing SOD1-G93A model with WT myeloid cells delays1018 Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc.disease progression (Beers et al., 2006). Therefore, we hypothe-
sized that if NF-kB activation is a mechanism by which mutant
SOD1 microglia mediates MN death in ALS, then disease pro-
gression will be substantially delayed in SOD1-G93A mice with
microglial NF-kB inhibition. Mice homozygous for IKKb (IKKbf/f),
both SOD1 and WT, displayed serious immune dysfunction and
could not be assessed for survival, so we generated SOD1;
CSF1R-cre; IKKbF/+ heterozygous mice. Strikingly, heterozy-
gous inhibition of NF-kB specifically in the myeloid lineage of
the fast-progressing SOD1-G93A mouse model significantly de-
layed disease progression by 47%, resulting in a 20 day increase
in survival. Therefore, our data extend those showing that ALS
microglia contribute to MN death in a non-cell-autonomous
mechanism, and we report that microglial-mediated MN death
in ALS occurs through an NF-kB-dependent mechanism.
Figure 7. NF-kB Activation in Wild-Type Microglia Induces MN Death
(A and B) Representative microscopic fields (A) and counts (B) of Hb9-GFP+MNs after 1 day (24 hr) and 3 days (72 hr) in coculture withWTmicroglia (white bar) or
WT microglia with constitutively active IKKb (IKKbCA) (black bar).
(C) Quantification of NF-kB activation (phospho-p65), normalized to total p65, both determined by ELISA.
(D) Immunoblot of lumbar spinal cord protein from WT and IKKbCA mice. The blot was probed for p-p65 (top), IKKb (top middle), p65 (bottom middle), and actin
(bottom). Phospho-p65 band intensities normalized to p65/Actin. Fold change determined by densitometry in Image J.
(E) Immunohistochemistry of lumbar spinal cords of WT and IKKbCA littermates at 8 months. Iba1-positive microglia (red), GFAP-positive astrocytes (blue), and
ChAT-positive MNs (green). Scale bar indicates 100 mm.
(F) Counts of ChAT+ MNs in ventral horn of lumbar spinal cord from 8-month-old IKKbCA and WT littermates (n=3).
(G andH)Mass (G) and grip strength (H) of IKKbCA (n=6) andWT littermates (n=8). Error bars represent SEM. *p<0.05, **p<0.01, and ****p< 0.0001. See alsoMovie
S6 and Figures S5 and S6.
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Microglia Induce Motor Neuron Death by NFkB in ALSTo determine the extent by which NF-kB inhibition in microglia
alters the neuroinflammatory hallmarks of ALS pathology, we
analyzed lumbar sections for astrogliosis, microgliosis, and MN
death. In SOD1-G93A; IKKbf/wt; CSF1R-cre+ mice with NF-kBinhibition in microglia, we observed a decrease in Iba-1 and
GFAP compared to age-matched cre-negative control litter-
mates, suggesting NF-kB inhibition delayed microglial activation
and astrogliosis during disease progression. Additionally, weNeuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc. 1019
Figure 8. The Classical NF-kB Pathway Mediates Microglial Activation and MN Death
(A) Model of the mechanism by which SOD1-G93Amicroglia induceMN death in ALS. The NF-kB pathway is initiated in SOD1-G93Amicroglia by a SOD1-G93A-
dependentmechanism leading tomicroglial activation and, subsequently, MNdeath via inflammatory pathways. Inhibition ofmicroglial NF-kB in ALSmice blocks
microglial activation, downregulates proinflammatory markers, and delays MN death.
(B) Model of IKKbCA mice in which NF-kB is constitutively active only in myeloid cells. Microglia in these mice exhibit a proinflammatory phenotype that induces
MN death in a mutant SOD1-independent mechanism.
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mice and in fact might be detrimental, which has been previously
reported (Crosio et al., 2011). It is likely NF-kB might regulate
important aspects of astrocyte function that are needed to sup-
port MNs under insult in ALS, which may explain why no benefit
was observed with astroglial NF-kB inhibition in SOD1-G93A
mice (Beattie et al., 2002; Bracchi-Ricard et al., 2008). These
data suggest that astrocytes elicit a different non-cell-autono-
mous mechanism than microglia to induce MN death in ALS.
To determinewhether the survival increase observed in SOD1-
G93A; IKKbf/wt; CSF-1R-cre+ mice was due to a dampened
proinflammatory microglial response, we characterized micro-
glia for known markers of microglial activation. Depending on
themilieu in which they become activated, microglia differentiate
into inflammatory (M1) and antiinflammatory (M2) effector cells
with the potential to kill invading pathogens or neurons (M1), pro-
mote tissue repair, or dampen the immune response (M2) (Kigerl
et al., 2009). These activation states were characterized initially
in macrophages in vitro and likely represent an oversimplification
of the in vivo functional potential of these cell types (Mosser and1020 Neuron 81, 1009–1023, March 5, 2014 ª2014 Elsevier Inc.Edwards, 2008; Ransohoff and Perry, 2009). Not surprisingly,
ALS microglia have a unique proinflammatory (M1) gene signa-
ture compared to LPS-stimulated M1 microglia (Chiu et al.,
2013). Previous reports showed an upregulation of genes in
SOD1-G93A mice known to be expressed by inflammatory
(or M1) microglia such as CD68, CD86, iNOS, TNF-a, NOX2,
COX2, IL-6, and IL-1b, which increase with disease progression.
In fact, SOD1-G93A; IKKbf/wt; CSF-1R-cre+ mice exhibited a
marked reduction in prototypic ALS microglia inflammatory
markers such as CD68, CD86, and iNOS compared to cre-nega-
tive controls, suggesting proinflammatory M1 microglia play a
central role in MN death in ALS (Figure 8A) (Beers et al., 2011a;
Henkel et al., 2009; Zhao et al., 2004). Additionally, a recent
report suggests infiltrating inflammatory monocytes contribute
to MN death in ALS (Butovsky et al., 2012). Since CSF1R-cre
is expressed inmicroglia and peripheral myeloid cells, we cannot
exclude the possibility that the delay in disease progression we
observe is due to NF-kB inhibition in peripheral macrophages
or infiltrating monocytes. To further address the contribution of
peripheral myeloid cells to ALS, new cre mouse strains or viral
Neuron
Microglia Induce Motor Neuron Death by NFkB in ALSvectors need to be developed that exclusively target microglia or
peripheral macrophages/monocytes.
Since NF-kB activation is the mechanism by which SOD1-
G93A microglia induce MN death, we hypothesized that consti-
tutively activating NF-kB in WT microglia should be sufficient to
induce MN death. Interestingly, microglia with constitutively
active NF-kB rapidly induced a 50% decrease in MN survival
in vitro compared to controls through a mechanism that is inde-
pendent of mutant SOD1. Notably, 8-month-old IKKbCA mice
exhibited a marked reduction in spinal MNs, accompanied by
reduced weight and grip strength, indicative of muscle atrophy.
Additionally, IKKbCA microglia showed increased levels of
CD68, CD86, and iNOS compared to WT, suggesting NF-kB
activation induces an inflammatory (M1) microglia phenotype
that causes MN death (Figure 8B). While we cannot determine
whether microglia or peripheral myeloid cells are inducing MN
death, these data have strong implications for patients with
familial mutations other than SOD1 and sporadic ALS patients.
Recently, immunohistochemical studies showed that NF-kB is
highly induced in microglia of sporadic patients, and those with
mutation in the gene optinuerin, a negative regulator of TNF-a,
induced NF-kB activation that has been shown to cause ALS
(Sako et al., 2012). Additionally, TDP-43 and FUS have been
shown to be coactivators of NF-kB, and NF-kB inhibition in
transgenic mice overexpressing mutant TDP-43 ameliorated
the disease phenotype (Swarup et al., 2011; Uranishi et al.,
2001). Furthermore, dysregulation of the NF-kB pathway in lym-
phoblastoid cell lines was identified by MetaCore analysis in
both C9ORF72 patients and non-C9ORF72 patients (Ismail
et al., 2013). Therefore, aberrant NF-kB activation could be
driving the microglial inflammatory response in both familial
and sporadic ALS and could be a universal therapeutic target
for ALS.
However, targeting NF-kB is complicated due to its diverse
functions in different cell types in the CNS and periphery. For
example, NF-kB activation in glutamatergic neurons is involved
in learning and memory, dendritic arborization, and axonal
outgrowth (Gutierrez et al., 2005; Kaltschmidt et al., 2006). In
the context of neurodegeneration, mice with selective inhibition
of IKKb in neuronal cells utilizing aCamkII cre-driver experienced
more severe EAE symptoms and succumb to disease earlier due
to their inability to induce neuronal expression of NF-kB-depen-
dent neuroprotective and antiapoptotic genes (Emmanouil et al.,
2009; Taoufik et al., 2011). Therefore, when targeting NF-kB in
the CNS, cell-type specificity is likely required so that functional
benefits achieved by dampening microglial inflammation are not
masked by neuronal deficits induced by off-target neuronal
NF-kB inhibition (Kaltschmidt and Kaltschmidt, 2009; Mattson
and Meffert, 2006).
The data presented here clearly demonstrate that NF-kB is a
promising therapeutic target for ALS. Heterozygous inhibition
of NF-kB in microglia substantially delayed disease progression
in the severe SOD1-G93A model. Strikingly, NF-kB activation in
WT microglia causes MN death in vitro as well as in vivo, inde-
pendent of mutant SOD1. This suggests traumatic events, envi-
ronmental risks, or predisposing genetic factors that lead to
chronic activation of NF-kB in microglia could trigger the patho-
genicmechanism leading toMN death. The present data provideimportant insight on how microglia induce MN degeneration in a
familial model of ALS, but even more interestingly, provide a
therapeutic target for both familial and sporadic ALS patients.
EXPERIMENTAL PROCEDURES
Transgenic Mice
All procedures were performed in accordance with the NIH Guidelines on the
care and use of vertebrate animals and approved by the Institutional Animal
Care and Use Committee of the Research Institute at Nationwide Children’s
Hospital. Transgenic female B6SJ/L(SOD1-G93A)1Gur/J mice and nontrans-
genic littermates (Jackson Laboratories) were utilized for time course immuno-
blot studies, primary cell isolations, and breeding with other transgenic lines.
SOD1 transgene copy number was confirmed by real-time PCR. See Supple-
mental Experimental Procedures for details.
Primary Cell Isolations
Adult microglia were isolated as previously described with minor modifications
(Moussaud and Draheim, 2010). Neonatal microglia were isolated from 3-day-
old pups as previously described with minor modifications (Xiao et al., 2007).
Adult primary astrocytes were isolated as previously described (Miranda et al.,
2012). See Supplemental Experimental Procedures for details.
Microglia/MN Coculture
Hb9-GFP+ MNs were plated in 96-well plates coated with laminin (5 mg/ml;
Invitrogen) at a density of 6,000 cells per well. The day after, microglia were
plated on top of MNs at a density of 35,000 cells per well in MN media
(DMEM:F12; Invitrogen), 5% horse serum, 2% N2 (Invitrogen), 2% B27
(Invitrogen) + GDNF (10 ng/ml, Invitrogen), BDNF (10 ng/ml, Invitrogen), and
CNTF (10 ng/ml, Invitrogen). The coculture plate was imaged each day by
the IN Cell Analyzer 6000 (GE Healthcare). Images were processed and
analyzed using IN Cell Developer Toolbox 1.9 and IN Cell AnalyzerWorkstation
3.7 software (GE Healthcare) to quantify number of surviving GFP+ MNs
per well.
Immunoblot Analysis
Cells and tissues were homogenized in Tissue Protein Extraction Reagent
(Pierce) with EDTA, Complete protease inhibitor (Roche), and Phospho-
STOP (Roche). Immunoblot analyses were performed as previously described
(Foust et al., 2013). See Supplemental Experimental Procedures for details.
Immunohistochemistry
Animals were deeply anesthetized with a lethal dose of xylazene/ketamine and
perfused transcardially with saline, then 4% paraformaldehyde. Spinal cords
were sectioned 40 mm thick using a vibrating blade microtome (Leica micro-
systems). Immunohistochemistry was performed as previously described
(Foust et al., 2013). See Supplemental Experimental Procedures for details.
Statistical Analyses
For all statistical tests, Graph Pad Prism 6 software (La Jolla) was used. Statis-
tical analysis of mean differences between groups was performed by either
Student’s t test or one- or two-way ANOVA, followed by a Bonferroni post
hoc analysis depending on the number of variables and time-points in each
experiment. All p values and n values are indicated in figure legends.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, six movies, and
Supplemental Experimental Procedures and can be found with this article
online at http://dx.doi.org/10.1016/j.neuron.2014.01.013.
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